The Evolving Landscape of HER2-Directed Breast Cancer Therapy
- 7 August 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Oncology
- Vol. 21 (10), 1-17
- https://doi.org/10.1007/s11864-020-00780-6
Abstract
Opinion statement The management of patients with HER2+ breast cancer has evolved significantly over the preceding decades. HER2 targeting strategies have advanced beyond focusing on the receptor alone to encompass a range of approaches. Current standard of care practices in these patients relies upon dual HER2 blockade with trastuzumab and pertuzumab in the adjuvant and metastatic settings. T-DM1 has proven particularly efficacious in patients with residual disease status post neoadjuvant therapy, with additional therapies approved in the subsequent lines to address recurrent and resistant disease. Advances continue to be made in HER2+ breast cancer with multiple novel agents on the horizon, employing diverse mechanisms of action that are described in this review.Keywords
This publication has 83 references indexed in Scilit:
- HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma TherapyPLOS ONE, 2013
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on TrastuzumabClinical Cancer Research, 2011
- Antitumor activity of HM781‐36B, a highly effective pan‐HER inhibitor in erlotinib‐resistant NSCLC and other EGFR‐dependent cancer modelsInternational Journal of Cancer, 2011
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseProceedings of the National Academy of Sciences of the United States of America, 2011
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerBreast Cancer Research and Treatment, 2010
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor ModelsCancer Research, 2009
- Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene, 2008
- Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based TherapyThe Oncologist, 2006
- Human T Cells Armed with Her2/neu Bispecific Antibodies Divide, Are Cytotoxic, and Secrete Cytokines with Repeated StimulationClinical Cancer Research, 2006
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000